VTX 806
Alternative Names: VTX-806Latest Information Update: 09 Sep 2024
At a glance
- Originator Vivet Therapeutics
- Developer CIMA- Universidad de Navarra; Vivet Therapeutics
- Class Gene therapies
- Mechanism of Action CYP27A1 protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cerebrotendinous xanthomatosis
Most Recent Events
- 05 Sep 2024 VTX 806 receives Orphan Drug status for Cerebrotendinous xanthomatosis in European Union
- 05 Sep 2024 Pharmacodynamics data from preclinical trials in Cerebrotendinous xanthomatosis released by Vivet Therapeutics
- 01 Feb 2024 Preclinical trials in Cerebrotendinous xanthomatosis in France (Parenteral) prior to February 2024